BioLineRx (BLRX) Long-Term Debt Issuances (2018 - 2026)
BioLineRx (BLRX) posted quarterly Long-Term Debt Issuances of -$113000.0 for Q4 2025, up 17.52% quarter-over-quarter from -$137000.0 in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Long-Term Debt Issuances (2018 - 2026) Analysis & Trends
BioLineRx's Long-Term Debt Issuances history runs 7 years deep, the most recent figure standing at -$113000.0 for Q4 2025.
- In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to -$113000.0; the TTM figure through Dec 2025 stood at -$512000.0 (down 102.66% YoY), while the FY2025 annual figure was -$512000.0, down 102.66% from the prior year.
- Long-Term Debt Issuances for Q4 2025 stood at -$113000.0, up from -$137000.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $19.4 million in Q2 2024, with the low at -$556000.0 in Q4 2022.
- The 5-year median for Long-Term Debt Issuances is -$93000.0 (2021), against an average of $1.5 million.
- Peak annual rise in Long-Term Debt Issuances reached 42578.26% in 2022, while the deepest fall reached 990.2% in 2022.
- BioLineRx's Long-Term Debt Issuances stood at -$51000.0 in 2021, then slumped by 990.2% to -$556000.0 in 2022, then soared by 78.06% to -$122000.0 in 2023, then soared by 15962.3% to $19.4 million in 2024, then tumbled by 100.58% to -$113000.0 in 2025.
- Business Quant data shows BLRX's Long-Term Debt Issuances at -$113000.0 in Q4 2025, -$137000.0 in Q3 2025, and -$135000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | BioLineRx | 6.46 Bn | 6.46 Bn | 235,000.00 | -1.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.12 Mn |
| Mar 31, 2026 | -1.12 Mn |
| Dec 31, 2025 | -1.14 Mn |
| Sep 30, 2025 | -1.12 Mn |
| Jun 30, 2025 | -1.12 Mn |
| Mar 31, 2025 | -1.12 Mn |
| Dec 31, 2024 | -11.97 Mn |
| Sep 30, 2024 | -914,000.00 |
| Jun 30, 2024 | -782,000.00 |
| Mar 31, 2024 | -765,000.00 |
| Dec 31, 2023 | -741,000.00 |
| Sep 30, 2023 | -802,000.00 |
| Dec 31, 2022 | -12.51 Mn |
| Sep 30, 2022 | 11.49 Mn |
| Jun 30, 2022 | -917,000.00 |
| Mar 31, 2022 | -895,000.00 |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | -854,000.00 |
| Jun 30, 2021 | -834,000.00 |
| Mar 31, 2021 | -814,000.00 |